Sort by 'likes'
Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. …
Medicine for the Mind
Living in the 21st century means less time, more stress; less standing more sitting; less walking more driving; less slow food, more fast food and less face time more Facebook. All this adds up to a very poor state of…
Diagnosing Aggressive Forms of Prostate Cancer With New Imaging Tests and Biomarkers
On this show we have the Associate Director, Department of Urology, Roswell Park Cancer Institute Dr. James Mohler discussing the recent NCCN guidelines for prostate cancer treatment and the latest research available to us that can help diagnose high risk…
The use of CLR 131 and other targeted radiotherapeutics in pediatric cancers
Many pediatric cancers have very poor overall survival rates once they relapse or if they do not respond to initial standard treatments. Radiotherapy plays an important role in the treatment of these cancers. However, if the cancer has metastasized to…
Understanding Multiple Myeloma: Types of Diagnostic Tests and Frequency
Myeloma presents itself differently in each patient. In order to understand your Myeloma and monitor it, you need to know which are the tests available and how often you have to get tested. No single test or study is adequate…